Table 1.
Completed phase 1 MAb trials in healthy volunteers identified by our review
| Reference | MAb | Number of healthy volunteers |
|---|---|---|
| [35] | (99 m)Tc-DI-DD-3B6/22-80B3 Fab’ (anti-D-dimer MAb Fab’ fragment) | 32 |
| [36], [37] | Abciximab (anti-glycoprotein IIb/IIIa receptor Fab) | 36 30 |
| [38] | AMG 317 (anti-interleukin-4 receptor MAb) | 60 |
| [39] | Anti-CD18 F(ab’)2 fragment | 53 |
| [40] | Anti-interleukin-10 MAb | 10 |
| [41] | Anti-Shiga toxins type 1 and 2 MAbs | 26 |
| [42] | ASKP1240 (anti-CD40 MAb) | 104 |
| [43] | B-E8 (anti-IL-6 MAb) | 24 |
| ClinicalTrials.gov | Belimumab (anti-B-cell activating factor MAb) | 118 |
| [44] | c alpha Stx2 (anti-Shiga toxin type 2 MAb) | 17 |
| ClinicalTrials.gov | Canakinumab (anti-interleukin-1 beta MAb) | 20 |
| [45] | CDA-1 (anti-Clostridium difficile toxin A MAb) | 30 |
| [46] | CMAB007 (anti-immunoglobulin E MAb) | 36 |
| [47] | Fanolesomab (anti-CD15 MAb) | 30 |
| [10] | GSK249320 (anti-myelin associated glycoprotein MAb) | 46 |
| [48] | GSK679586 (anti-interleukin-13 MAb) | 56 |
| [49] | IC14 (anti-CD14 MAb) | 16 |
| [50] | KBPA-101 (anti-Pseudomonas aeruginosa serotype O11 MAb) | 32 |
| [51] | MAb C23 (anti-cytomegalovirus MAb) | 20 |
| [52] | MDX-1303 (anti-Bacillus anthracis MAb) | 46 |
| [53] | MEDI-528 (anti-interleukin-9 MAb) | 53 |
| [54] | MGAWN1 (anti-West Nile virus MAb) | 40 |
| [55] | Motavizumab (anti-respiratory syncytial virus MAb) | 30 |
| [56] | PAm (anti-Bacillus anthracis MAb) | 105 |
| [57] | R297 (anti-Rhesus factor D MAb) | 25 |
| [58] | Raxibacumab (anti-Bacillus anthracis MAb) | 333 |
| [59] | REGN727(anti-proprotein convertase subtilisin/kexin 9 MAb) | 72 |
| [60] | Rovelizumab (anti-CD11/CD18 MAb) | 20 |
| [61] | RSHZ19 (anti-respiratory syncytial virus MAb) | 26 |
| [62] | SB 249417 (anti-factor IX MAb) | 26 |
| [63], [64] | TB-402 (anti-factor VIII MAb) | 24 56 |
| [65] | TCN-032 (anti-influenza virus MAb) | 40 |
| [66] | Tefibazumab (anti-Staphylococcus aureus MAb) | 19 |
| [2] | TGN1412 (anti-CD28 MAb) | 8 |
| [67] | TRX1 (anti-CD4 MAb) | 9 |
| [68], [69] | YM337 (glycoprotein IIb/IIIa inhibitor) | 53 18 |
Fab fragment antigen-binding region of a MAb.